Evaluating a new treatment for primary aldosteronism using adrenal artery embolization
Official title: The First Affiliated Hospital of Xinjiang Medical University
Run by Xinjiang Medical University · NCT06513676 · Data updated 2026-11-12
This study is testing a new treatment called adrenal artery embolization to see if it can help people with primary aldosteronism who can’t take medication or have surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Xinjiang Medical University Academic / other |
| Locations | 1 site (Ürümqi, Xinjiang) |
| Status | Recruiting |
| Started | April 15, 2024 |
| Main results expected | June 1, 2026 |
| Study ends | August 1, 2028 |
| Registry record updated | July 23, 2024 |
| Trial ID | NCT06513676 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-60 diagnosed with primary hyperaldosteronism who cannot tolerate medication or surgery.
✕Probably not a fit
Patients with severe hypersensitivity to contrast media or other forms of secondary hypertension may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the efficacy and safety of adrenal vein blood extraction and super selective adrenal artery embolization (SAAE) for patients with primary aldosteronism. It involves a prospective, multicenter approach to classify types of primary hyperaldosteronism and explore SAAE as a potential treatment alternative for those who cannot tolerate medication or surgery. The study will provide new evidence for the diagnosis and treatment of this condition, promoting the development of SAAE as a viable option.
Why it matters
Potential benefit: If successful, this study could offer a new treatment option for patients with primary aldosteronism who have limited responses to existing therapies.
How similar studies have gone: While the approach of adrenal artery embolization is relatively novel, similar studies have shown promise in treating conditions related to hyperaldosteronism.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-60 years old; * Primary hyperaldosteronism was diagnosed in strict accordance with the 2016 International Endocrine Society clinical guidelines; * Refusal of medication due to adverse reactions, refusal of adrenal resection due to surgical risk, or persistent hyperaldosteronism and cortical insufficiency after adrenal resection; * The patients and their families were introduced in detail to all the current treatment methods for primary aldosteronism, and the adrenal artery embolization was voluntarily accepted; Exclusion Criteria: * A history of severe hypersensitivity to contrast media; * There are serious complications of liver disease, such as thrombocytopenia, esophageal variceal bleeding, etc; * Renal insufficiency (serum creatinine \> 176mmol/L or estimated glomerular filtration rate \< min.1.73m2); * Combined with other secondary hypertension, such as pheochromocytoma, hypercortisolism, renal vascular hypertension (such as renal artery stenosis), renin secretory tumor, renal parenchymatous hypertension, drug-induced hypertension (such as long-term use of glucocorticoids, contraceptives, estrogens, herbs containing glycyrrhizin), pregnancy hypertension and other secondary hypertension; * Hereditary diseases: such as false aldosteronism (Liddle syndrome), Bartter syndrome, familial hypokalemia and hypomagnesemia (Gitelman syndrome); * Cerebral apoplexy, myocardial infarction and stent implantation occurred in the past 3 months; * Serious other basic, such as heart dysfunction (grade IV), acute infection, autoimmune diseases, various malignant tumors and so on; * Participated in other clinical trials within the past 3 months; * Individual pregnancy, nursing or planning pregnancy;
Where it's running
-
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China Recruiting
Study contacts
- Study coordinator: Xiang Xie
- Email: xiangxie999@sina.com
- Phone: +869914366892
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Kidney stiffness measured by ultrasound in hypertension and healthy volunteers
This study tests whether kidney stiffness measured by a non-invasive ultrasound method differs between people with high blood pressure and healthy individuals.
-
Inclisiran vs. Statin for Primary Aldosteronism
This trial tests whether inclisiran plus amlodipine works differently from a statin-based approach in people with primary aldosteronism and high blood pressure.
-
Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.
-
Metomidate PET-CT vs Usual Care for Primary Aldosteronism
This study tests whether [11C] metomidate PET-CT can help orient treatment for people with primary aldosteronism compared with the usual adrenal venous sampling approach.
-
Captopril Test with LC-MS/MS for Aldosterone and Renin in Primary Aldosteronism
This study tests whether measuring aldosterone with LC-MS/MS during a captopril test can better diagnose primary aldosteronism.
-
Finerenone vs. Spironolactone for Primary Aldosteronism
This trial tests whether finerenone works as well as spironolactone to lower blood pressure and improve related health measures in adults with primary aldosteronism.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.